⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Since the explosive growth in demand for GLP-1 receptor agonists beginning in 2023, India has faced a persistent supply challenge. Ozempic (semaglutide 0.5 mg and 1 mg), Rybelsus (oral semaglutide), and Mounjaro (tirzepatide) have been intermittently unavailable at pharmacies across major cities. Waiting periods of weeks to months have driven many patients toward alternative sources: compounding pharmacies, online vendors, social media sellers, and grey-market imports.
This guide explains the legal landscape, the real risks involved, and how to get genuine GLP-1 medications safely in India.
Consult your healthcare provider before starting any medication. Never purchase prescription medications without a valid prescription from a registered medical practitioner.
As of mid-2026, the following GLP-1 medications are approved by the Central Drugs Standard Control Organisation (CDSCO) and legally available in India with a valid prescription:
| Medication | Generic Name | Manufacturer | CDSCO Status |
|---|---|---|---|
| Ozempic (0.5 mg, 1 mg pen) | Semaglutide | Novo Nordisk | Approved — Type 2 diabetes |
| Rybelsus (3 mg, 7 mg, 14 mg) | Oral semaglutide | Novo Nordisk | Approved — Type 2 diabetes |
| Mounjaro (2.5–15 mg pen) | Tirzepatide | Eli Lilly | Approved — Type 2 diabetes |
| Victoza (1.2 mg, 1.8 mg pen) | Liraglutide | Novo Nordisk | Approved — Type 2 diabetes |
| Saxenda (3 mg pen) | Liraglutide | Novo Nordisk | Approved — Obesity/weight management |
Wegovy (semaglutide 2.4 mg for obesity) does not yet have separate CDSCO approval as of mid-2026 — it is sometimes imported for personal use but is not officially marketed in India.
A compounding pharmacy prepares medications individually — typically when a commercially available product is unavailable, when a patient needs a modified dose form, or when a specific patient population requires customisation.
In India, compounding is legal under Schedule L of the Drugs and Cosmetics Act, 1940, when performed by a licensed pharmacist and only for a specific patient with a valid prescription.
However: Compounding is permitted for drugs that are commercially available only under very limited circumstances — generally when the commercial product is genuinely unavailable in the required dose form for a specific patient. Compounding is NOT a pathway to create generic versions of patented branded medications.
Some Indian compounding pharmacies — particularly in large cities — are advertising semaglutide injection solutions prepared in-house. The risks include:
Numerous Telegram groups, Instagram accounts, and websites are advertising GLP-1 pens at below-market prices, often framed as "imported" or "direct from manufacturer."
Red flags that indicate a fraudulent or unregulated source:
Some patients source genuine Ozempic or Mounjaro pens from overseas — typically the UK, USA, UAE, or Turkey — through personal importation or via agents.
The legal position: Importing prescription medications for personal use without a valid Indian prescription and CDSCO import licence is technically illegal under the Drugs and Cosmetics Act. Customs routinely seizes such shipments.
The practical risk: Even genuinely manufactured pens can be rendered ineffective if not stored properly during transit. Semaglutide exposed to temperatures above 30°C for extended periods loses potency.
A particularly dangerous category: websites selling "research-grade semaglutide" or "semaglutide acetate" as a powder for self-reconstitution. These are marketed for "research purposes" but are clearly targeted at self-injecting patients.
These products are extremely dangerous:
Do not use research-grade peptides under any circumstances.
When purchasing GLP-1 medications in India, verify:
Counterfeit products are sometimes priced identically to genuine ones to appear legitimate. Low price is a red flag, but normal price does not guarantee authenticity.
Do not share or transfer GLP-1 pens between patients — pens are single-patient devices, and needle re-use creates infection risk.
GLP-1 pens are calibrated for specific doses. Attempting to extract medication from a partially used pen to create additional doses is not safe and will likely result in incorrect dosing.
Q: Is it safe to use compounded semaglutide if my doctor prescribes it?
Indian doctors do not have the authority to prescribe compounded semaglutide when the original product is commercially available — even if it is temporarily out of stock. If a doctor is prescribing compounded semaglutide routinely, be cautious about the legality and safety of that arrangement.
Q: A pharmacy in my city is selling "imported Ozempic" without a prescription. Is it safe?
No — selling prescription medications without a valid prescription is illegal under Indian law regardless of the medication's origin. A legitimate seller will always require a prescription. The absence of this requirement is itself a red flag.
Q: I ordered Ozempic from abroad and it arrived damaged or different-looking. What should I do?
Do not use the medication. Report it to CDSCO's online vigilance portal and contact your prescribing doctor. Damaged, improperly stored, or unusual-looking pens should never be injected.
Q: What if I simply cannot afford genuine Ozempic or Mounjaro?
Discuss affordability explicitly with your endocrinologist. Options may include:
Contact your prescribing doctor if:
Patient safety depends on medication quality. The short-term cost saving from unregulated sources is not worth the risk of receiving ineffective, contaminated, or incorrectly concentrated medication.
